FundedIQ
Biotechnology

Capricor Therapeutics: Funding, Investors & Team (Sep 2026)

Capricor Therapeutics is a biotechnology company that specializes in creating and bringing to market cell and exosome-based therapeutics for fighting diseases. They are currently working on CAP-1002, a cell therapy option for Duchenne muscular dystrophy and COVID-19. The company was established in 2005 and is based in Los Angeles, California.

www.capricor.com LinkedIn Los Angeles, United States 101-250 employees
Biotechnology Health Care Medical Therapeutics
Total raised
$165M
Rounds
2
Latest
Undisclosed round
Dec 2025

Capricor Therapeutics has raised $165M across 2 funding rounds on record, the most recent an undisclosed round of $150M announced in Dec 2025.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Capricor Therapeutics Company Profile and Key Stats

Total funding raised
$165M
across 2 rounds on record
Funding rounds on record
2
Latest funding round
Undisclosed round
$150M in Dec 2025
Employees
101-250
reported band
Headquarters
Los Angeles, United States

Latest funding round on record: Dec 2025.

Capricor Therapeutics Funding Rounds

Date
Round
Amount
Undisclosed round
$150M
Undisclosed round
$15.0M

Capricor Therapeutics raised $15.0M in an undisclosed round announced in Sep 2024.

1.3 years later, an undisclosed round of $150M was announced in Dec 2025.

Capricor Therapeutics Founders and Leadership Team

Name
Role
Contact
Linda Marban
Founder
Locked

Contact details for the Capricor Therapeutics team: 1 of 1 has an email address on file.

Start 14-day free trial →

Capricor Therapeutics Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M

Capricor Therapeutics' latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Capricor Therapeutics in Biotechnology and Los Angeles

Companies Similar to Capricor Therapeutics

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Capricor Therapeutics Funding FAQs

What does Capricor Therapeutics do?

Capricor Therapeutics is a biotechnology company that specializes in creating and bringing to market cell and exosome-based therapeutics for fighting diseases. They are currently working on CAP-1002, a cell therapy option for Duchenne muscular dystrophy and COVID-19. The company was established in 2005 and is based in Los Angeles, California.

How much funding has Capricor Therapeutics raised?

Capricor Therapeutics has raised $165M across 2 rounds on record. The most recent is an undisclosed round of $150M announced in Dec 2025.

When did Capricor Therapeutics last raise funding?

Capricor Therapeutics' most recent funding round on record is an undisclosed round of $150M, announced in Dec 2025.

Who founded Capricor Therapeutics?

FundedIQ lists Linda Marban (Founder) at Capricor Therapeutics.

Where is Capricor Therapeutics headquartered?

Capricor Therapeutics is based in Los Angeles, California, United States.

How many employees does Capricor Therapeutics have?

Capricor Therapeutics is in the 101-250 employee band.

How does Capricor Therapeutics' funding compare to other Biotechnology startups?

Capricor Therapeutics' latest round of $150M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's Capricor Therapeutics Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Capricor Therapeutics is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.